Job title: Chief Scientific Officer
Rich’s career in biotechnology stretches back to 1989, when he joined Genzyme R&D in Framingham MA. In 1990, his group at Genzyme was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) protein and to determine the molecular defect caused by the most common mutation of CFTR. Over the next 25 years, Rich held a number of roles of increasing responsibility at Genzyme, including Head of Research and, following Sanofi’s acquisition of Genzyme, Head of R&D. In January of 2015 Rich joined ImmunoGen, where he oversees research leading to new ADCs. He is the co-author of over 60 peer-reviewed publications and 23 issued U.S. patents in the area of biotechnology. Richard is a Fellow of the American Institute for Medical and Biological Engineering.